Senti Biosciences, Inc.
$1.14
▲
2.07%
2026-04-21 09:31:02
www.sentibio.com
NCM: SNTI
Explore Senti Biosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$34.26 M
Current Price
$1.14
52W High / Low
$5.1 / $0.77
Stock P/E
—
Book Value
$0.18
Dividend Yield
—
ROCE
-171.08%
ROE
-2.18%
Face Value
—
EPS
$-2.75
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
2.12
Debt / Equity
516.93
Current Ratio
1.67
Quick Ratio
1.67
Forward P/E
-0.98
Price / Sales
1,235.73
Enterprise Value
$39.34 M
EV / EBITDA
-0.72
EV / Revenue
1,788.27
Rating
Strong Buy
Target Price
$11
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Rezolute, Inc. | $3.37 | — | $322.5 M | — | -48.84% | -74.02% | $11.46 / $1.07 | $1.23 |
| 2. | Dyadic International, Inc. | $0.88 | — | $31.88 M | — | -114.18% | -3.98% | $1.35 / $0.65 | $0.03 |
| 3. | Aclaris Therapeutics, Inc. | $4.25 | — | $512.53 M | — | -53.3% | -50.2% | $4.89 / $1.08 | $0.85 |
| 4. | Relay Therapeutics, Inc. | $16.4 | — | $3 B | — | -50.82% | -41.12% | $17.32 / $2.53 | $3.26 |
| 5. | CervoMed Inc. | $3.97 | — | $36.76 M | — | -155.27% | -93.92% | $13.13 / $3.51 | $1.97 |
| 6. | Protagonist Therapeutics, Inc. | $104.42 | — | $6.74 B | — | -25.39% | -20.18% | $107.84 / $41.28 | $9.82 |
| 7. | Aditxt, Inc. | $0.35 | — | $0.39 M | — | -318.91% | -6.99% | $2,594.48 / $0.39 | $-151.87 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.02 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -13.58 M | -16.95 M | -16.8 M | -16.4 M | -16.17 M | — |
| Net Profit | -14.47 M | -18.13 M | -14.73 M | -14.11 M | -0.61 M | — |
| EPS in Rs | -0.46 | -0.58 | -0.47 | -0.45 | -0.02 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.02 M | 0 M | 1.98 M | 3.29 M |
| Operating Profit | -63.73 M | -60.73 M | -66.77 M | -62.08 M |
| Net Profit | -61.44 M | -52.79 M | -71.06 M | -58.21 M |
| EPS in Rs | -1.97 | -1.7 | -2.28 | -1.87 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 51.22 M | 97.84 M | 119.48 M | 180.79 M |
| Total Liabilities | 45.63 M | 72.19 M | 52.57 M | 53.53 M |
| Equity | 5.59 M | 25.65 M | 66.91 M | 127.26 M |
| Current Assets | 23.27 M | 58.96 M | 71.2 M | 102.58 M |
| Current Liabilities | 13.97 M | 13.15 M | 12.67 M | 18.05 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -43.44 M | -41.4 M | -52.4 M | -34.9 M |
| Investing CF | -0.18 M | 0.03 M | 30.08 M | -81.96 M |
| Financing CF | 11.76 M | 53.73 M | 0.78 M | 118.55 M |
| Free CF | -43.64 M | -41.42 M | -64.43 M | -76.27 M |
| Capex | -0.2 M | -0.03 M | -12.04 M | -41.37 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -100% | -39.81% | — | — |
| Earnings Growth % | 25.71% | -22.07% | — | — |
| Profit Margin % | — | -3592.42% | -1771.45% | — |
| Operating Margin % | — | -3375.38% | -1889.35% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | -3100.91% | -1770.05% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-07-18 | 1:0.1 |